This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Amakem Sponsors Ophthalmology Chair At KU Leuve

DIEPENBEEK, Belgium, April 8, 2013 /PRNewswire/ --

Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has sponsored a new Chair of Ophthalmology Translational Research at the Catholic University Leuven (KU Leuven), Belgium.

The Chair has been established by the University and Amakem to drive further translational research into the prevention of diseases leading to impaired vision or blindness with a special emphasis on glaucoma. It will be held by Professor Ingeborg Stalmans, head of the glaucoma clinic of the Ophthalmology Department at the University Hospital in Leuven (UZLeuven). Professor Stalmans also runs an ophthalmology laboratory at KU Leuven and is a member of Amakem's Clinical Advisory Board.

Professor Stalmans said: "Amakem is a relatively young company to sponsor a Chair at a leading University and it is a measure of the maturity of their approach. As a member of the Amakem Clinical Advisory Board, I have had the opportunity to work closely with them as they have advanced AMA0076 into the clinic as a highly promising new treatment for glaucoma and ocular hypertension. I am grateful for the opportunity presented by the Chair to advance work into the science underlying glaucoma and other diseases and look forward to this work being translated into new medicines."

The KU Leuven Chair sponsorship is intended to further fundamental research and the Chair holder is appointed by the Rector of the University on the recommendation of the Dean of the relevant faculty. The Chair holder can use the gift to fund teaching or research. Amakem has initially committed to funding the Chair for three years.

Dr. Jack Elands, CEO of Amakem, said: "It is with great pride that we make this announcement. We have already established a very strong relationship with KU Leuven  and this sponsorship will serve to build on that and provide valuable funding to research aimed at improving treatment for patients with sight threatening conditions. We look forward to new insight being generated, particularly improved understanding of the causes and potential treatment of glaucoma."

In healthy eyes, aqueous humor flows through the eye and exits, primarily via the trabecular meshwork, to maintain the appropriate intraocular pressure. In glaucoma, increased pressure leads to damage of the optic nerve resulting in vision loss and ultimately blindness. It is expected that Prof. Stalmans will focus part of her work as Chair of Ophthalmology Translational Research on strategies to improve eye health by restoring the function of the trabecular meshwork.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs